home / stock / abvc / abvc news

ABVC News and Press, ABVC BioPharma Inc.

Stock Information
Company Name: ABVC BioPharma Inc.
Stock Symbol: ABVC
Market: NASDAQ
Website: abvcpharma.com
Menu
ABVC ABVC Quote ABVC Short ABVC News ABVC Articles ABVC Message Board
Get ABVC Alerts

News, Short Squeeze, Breakout and More Instantly...
ABVC - ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
ABVC - ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI

FREMONT, CA - ( NewMediaWire ) - July 9, 2024 -   ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...

ABVC - ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

FREMONT, CA  - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...

ABVC - ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market

The Company holds a U.S. patent for the same treatment FREMONT, CA - ( NewMediaWire ) - June 25, 2024 - ABVC BioPharma, Inc.   (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, a...
ABVC - ABVC Biopharma files to sell 1M shares of common stock for holders

2024-06-21 17:26:44 ET More on ABVC BioPharma ABVC BioPharma executes licensing agreement with OncoX ABVC Biopharma stock climbs on deal for its oncology/hematology products Financial information for ABVC BioPharma Read the full article on Seeking Alpha ...

ABVC - ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue

FREMONT, CA - ( NewMediaWire ) - June 12, 2024 -   ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company receive...

ABVC - Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M

US FDA-IND 131300 (ABV-1702)   FREMONT, CA - ( NewMediaWire ) - May 24, 2024 -   ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncol...
ABVC - ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M

FREMONT, CA - ( NewMediaWire ) - May 22, 2024 -   –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a  Corporate...

ABVC - Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M

  FREMONT, CA - ( NewMediaWire ) - May 15, 2024 -   ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today ...

ABVC - Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

FREMONT, CA - ( NewMediaWire ) - May 09, 2024 -   ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that in its fi...
Next 10